← FDA DRUG APPROVALS

FDA ANDA · ANDA088557

CHLOROTHIAZIDE AND RESERPINE

Sponsor: HIKMA

APPLICATION
ANDA088557
TYPE
ANDA
ORIGINAL APPROVAL
1983-12-22
LATEST ACTION
1990-09-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CHLOROTHIAZIDE AND RESERPINEDiscontinued
CHLOROTHIAZIDE 250MG, RESERPINE 0.125MG · TABLET · ORAL

Approval history

1990-09-20Manufacturing (CMC) · Supplement 9AP
1989-03-17Labeling · Supplement 11AP
1989-03-17Labeling · Supplement 7AP
1983-12-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →